Jan. 16	RTW Biotech's portfolio firm Penumbra acquired by Boston Scientific	AN
Jan. 12	RTW Biotech portfolio firm Aktis raises USD318 million in US IPO	AN
Jan. 12	British Land CEO to leave; Heathrow posts record year	AN
Jan. 12	Aktis announces $318 million IPO	RE
Dec. 18	RTW Biotech invests USD5.9 million in Yarrow Bioscience funding round	AN
Dec. 18	RTW Bio Injects $6 Million in Yarrow Bioscience's Series A Funding Round	MT
Dec. 18	RTW Biotech Opportunities announces new investment in Yarrow Bioscience	RE
Dec. 04	RTW Biotech Opportunities Ltd(LSE:RTW) added to FTSE 250 Index	CI
Dec. 04	RTW Biotech Opportunities Ltd(LSE:RTW) added to FTSE 350 Index	CI
Dec. 04	RTW Biotech Opportunities Joins FTSE 250 Index	MT
Dec. 04	FTSE 100 slips despite European rally as SSE falls	AN
Dec. 04	Ofgem approves GBP28 billion energy grid investment	AN
Dec. 04	RTW Biotech Opportunities joins FTSE 250 index	RE
Nov. 14	RTW Biotech Opportunities reports unaudited NAV attributable to ordinary shares as at 31 Oct $2.37 per share	RE
Nov. 07	RTW Biotech notes investee Evommune's USD150 million IPO raise	AN
25-10-31	RTW Biotech announces royalty funding agreement with Savara	AN
25-10-31	RTW Biotech Opportunities Notes Savara-RTW Funds' $75 Million Royalty Funding Deal	MT
25-10-31	RTW Biotech Opportunities says Savara announces $75 million funding agreement with co	RE
25-10-27	RTW Biotech hails Novartis acquisition of investee Avidity	AN
25-10-27	RTW Biotech Opportunities Ltd says Novartis to acquire Avidity Biosciences	RE
25-10-20	RTW Biotech Opportunities extends buyback by USD15 million	AN
25-10-15	RTW Biotech invests USD7.4 million in financing round for Kailera	AN
25-10-10	Akero says new owner Novo Nordisk to drive commercialisation process	AN
25-09-23	RTW Biotech lifts NAV on Biogen's USD85 million Alcyone deal	AN
25-09-23	Rtw biotech announces Biogen to acquire Alcyone Therapeutics	RE

Chart RTW Biotech Opportunities Ltd

Duration

Period

RTW: Dynamic Chart

RTW Biotech Opportunities Ltd is a Guernsey-based focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. The Company invests in companies developing therapies and technologies that can significantly improve patients' lives. The Company seeks to achieve its investment objective by leveraging the Investment Manager's data driven pipeline of assets to invest in life sciences companies across various therapeutic categories and product types (including genetic medicines, biologics, traditional modalities, such as small molecule pharmaceuticals and antibodies, and medical devices). It intends to create a diversified portfolio of investments across a range of businesses, each pursuing the development of superior pharmacological or medical therapeutic assets to enhance the quality of life and/or extend patient life. The Company's portfolio is managed by RTW Investments, LP.

Employees

Sector

Closed End Funds

Calendar

Mar. 25 - Q4 2025 Earnings Release (Projected)

More about the company